Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human thrombopoietin for platelet recovery in DCAG-treated intermediate-high-risk myelodysplastic syndrome
ChiCTR2000038982Phase 4Completed
- Sponsor
- Henan Provincial People's Hospital
- Start
- May 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by Henan Provincial People's Hospital. Primary endpoint: Platelet recovery time. Started May 2018; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000038982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038982.